Health news
The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for mirvetuximab soravtansine, for the treatment of patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been…
Many reports of cancer drug trials frame quality of life (QOL) outcomes in an inaccurate or misleading way, according to research published in JAMA Oncology. Researchers found favorable reports of QOL outcomes for roughly half…
The Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer. Nemvaleukin alfa is an investigational engineered fusion protein composed of…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021